- #1
Superman1271
- 21
- 0
Hi,
There is a lot of controversy over gene patenting. What are your thoughts on the subject?
There is a lot of controversy over gene patenting. What are your thoughts on the subject?
Superman1271 said:Hi,
There is a lot of controversy over gene patenting. What are your thoughts on the subject?
digital_biscu said:Apparently according to my friend who works in IP you cannot patent a gene!
Gene sequences that have been created in a lab can be patentedWoopydalan said:I thought gene's were patentable for some reason...wasn't sure how someone could call claims to them, but interesting topic to bring up.
Superman1271 said:Hi,
There is a lot of controversy over gene patenting. What are your thoughts on the subject?
Myriad don't have patents on BRCA1/2 (as far as I am aware you cannot patent something that has naturally formed) but they do have patents in the US on the current methods of isolating and detecting these genes. In other words they currently have a monopoly on the research equipment and thus research. Wiki has a good summary:Superman1271 said:Myriad Genetics hold patents on the BRCA1/BRCA2 genes, and apparently they have been very aggressive of defending these patents.
BRCA1 patent said:Methods to isolate and detect BRCA1 and BRCA2 were patented in the United States by Myriad Genetics. This US patent has been challenged by the American Civil Liberties Union. On March 29, 2010, a coalition led by the American Civil Liberties Union (ACLU) successfully challenged the basis of Myriad’s patents in New York District Court. The patent was invalidated, but the decision was appealed. On July 29, 2011 the United States Court of Appeals for the Federal Circuit made their decision and ruled that Myriad's patents are valid.
Effect on Gene Testing
The conditions of Myriad’s BRCA patent require that the only laboratories legally allowed to test and sequence the genes are the ones affiliated with Myriad. This exclusive control over BRCA testing, guaranteed by the patent, has prevented peer-reviewed validation of the tests provided by Myriad.
Since the BRCA test is marketed directly to the consumer, it is not subject to government oversight by agencies like the FDA. Without this government review, gene tests must be studied and assessed by scientific colleagues in a peer review. However, the kind of studies needed to validate the tests require access to the BRCA genes, which are protected by Myriad’s restrictive patent. Thus, without access to the genes or the methods used to sequence them, peer review of the test’s effectiveness is virtually impossible.
However, the patents have yet to be enforced in Europe, where BRCA research and testing is becoming more widely available, and several laboratories are currently offering their own BRCA testing. The UK firm NewGene offers the test at a very competitive price, to the NHS, its owner, only.
Legal decisions surrounding the BRCA1 and BRCA2 patents hold particular bearing on the field of genetic testing, as the field is relatively young. Until legal guidelines can be applied to the practice of gene testing, progress in the field will likely suffer due to uncertainty. Any decision made regarding the BRCA patents will likely become precedent for future disputes over the use of genes for testing.
Gene patenting is the process of granting exclusive rights to an individual or organization for a specific gene sequence. This means that no one else can use, sell, or research that gene without the patent holder's permission.
Gene patenting can incentivize companies and researchers to invest time and money into discovering and developing new genes, leading to advancements in medicine and technology. It can also provide financial benefits for patent holders and their investors.
One of the main concerns is that gene patenting can limit access to important genetic information, hindering progress and potentially limiting options for patients in need of treatment. It can also create monopolies and drive up prices for genetic testing and treatments.
Gene patenting can restrict the ability of other researchers to use certain gene sequences in their studies, which could slow down the pace of scientific discovery. It can also limit collaboration and sharing of information between researchers, hindering progress in the field.
This is a highly debated topic and opinions vary. Some argue that gene patenting goes against the fundamental idea of open access to knowledge and information, while others believe it is necessary to protect the intellectual property of those who invest in genetic research.